Full Data For Seattle Genetics' Lymphoma Drug Shine Bright Light On Antibody Drug Conjugates
This article was originally published in The Pink Sheet Daily
Executive Summary
Pivotal trial data look good for soon-to-be-filed orphan lymphoma candidate, partnered with Takeda. SGN-35 may be among the first conjugates to hit the U.S. market, with launch projected for third quarter 2011.